Otsuka to acquire Neurovance in $100m deal
Otsuka Pharmaceutical has agreed to acquire Neurovance, a privately held clinical stage pharma company.
The agreement, which was announced yesterday, March 2, will see Otsuka pay $100 million upfront and up to $150 million in additional payments.
US-based Neurovance is developing centanafadine, a treatment for attention-deficit hyperactivity disorder (ADHD).
Neurovance is based in Cambridge, Massachusetts, and was established as a spin-off from Euthymics Bioscience in 2011.
Tatsuo Higuchi, president and executive director of Otsuka, said: “Otsuka has been investing prudently in acquiring assets and collaborating on the development of new technologies that address specific patient needs in the central nervous system, cardio-renal and oncology therapeutic areas.”
He added that Neurovance’s resources will be a “welcome” and “integral part” of Otsuka’s activities.
The transaction is expected to close in the second quarter of 2017.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk